Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Receivables - Accured (2016 - 2025)

Celldex Therapeutics (CLDX) has 4 years of Revenue - Other data on record, last reported at $2.3 million in Q1 2013.

  • For Q1 2013, Revenue - Other changed 0.43% year-over-year to $2.3 million; the TTM value through Dec 2013 reached $2.3 million, down 78.34%, while the annual FY2013 figure was $2.3 million, 78.34% down from the prior year.
  • Receivables - Accured reached $4.4 million in Q4 2025 per CLDX's latest filing, down from $6.0 million in the prior quarter.
  • Across five years, Receivables - Accured topped out at $6.2 million in Q2 2025 and bottomed at $300000.0 in Q2 2021.
  • Average Receivables - Accured over 5 years is $2.7 million, with a median of $1.3 million recorded in 2021.
  • Peak YoY movement for Revenue - Other: skyrocketed 123.53% in 2011, then fell 6.31% in 2012.
  • A 4-year view of Revenue - Other shows it stood at $1.7 million in 2010, then soared by 42.82% to $2.4 million in 2011, then soared by 50.59% to $3.6 million in 2012, then plummeted by 34.27% to $2.3 million in 2013.
  • Per Business Quant database, its latest 3 readings for Revenue - Other were $2.3 million in Q1 2013, $3.6 million in Q4 2012, and $3.0 million in Q3 2012.